Abstract: Embodiments are directed towards polyolefin compositions including a high molecular weight polyolefin and a low molecular weight polyolefin.

Abstract: In various embodiments, a polyethylene formulation has a density of greater than 0.940 g/cm3 when measured according to ASTM D792, and a high load melt index (I21) of 1.0 g/10 min to 10.0 g/10 min when measured according to ASTM D1238 at 190° C. and a 21.6 kg load. Moreover, the polyethylene formulation has a peak molecular weight (Mp(GPC)) of less than 50,000 g/mol, a number average molecular weight (Mn(GPC)) of less than 30,000 g/mol, and a weight fraction (w1) of molecular weight (MW) less than 10,000 g/mol of less than or equal to 10.5 wt %, as determined by Gel Permeation Chromatography (GPC). Articles made from the polyethylene formulation, such as articles made by blow molding processes are also provided.

Abstract: In various embodiments, a bimodal polyethylene composition may have a density (?) from 0.952 g/cm3 to 0.957 g/cm3, a high load melt index (I21) from 1 to 10 dg/min, and a z-average molecular weight (Mz(GPC)) from 3,200,000 to 5,000,000 g/mol. The bimodal polyethylene composition may also have a peak molecular weight (Mp(GPC)) defined by the equation: Mp(GPC)<?2,805.3 MWD+102,688, wherein MWD is a molecular weight distribution defined by the equation: MWD=Mw(GPC)/Mn(GPC), Mw(GPC) is a weight average molecular weight of the bimodal polyethylene composition, Mn(GPC) is a number average molecular weight of the bimodal polyethylene composition. Additionally, the bimodal polyethylene composition has a ratio of the (Mz(GPC)) to the Mw(GPC) from 8.5 to 10.5. Articles made from the bimodal polyethylene composition, such as articles made by blow molding processes, are also provided.

Abstract: A low-density polyethylene having a melt strength measured at 190 C that is greater than or equal to 5.5 cN, a density that is greater than or equal to 0.9210 g/cm3 and less than or equal to 0.9275 g/cm3, and, and a melt index I2 measured at 190° C. that is greater than or equal to 4.5 g/10 min.

Abstract: A bimodal poly(ethylene-co-1-alkene) copolymer comprising a higher molecular weight poly(ethylene-co-1-alkene) copolymer component and a lower molecular weight poly(ethylene-co-1-alkene) copolymer component. The copolymer is characterized by a unique combination of features comprising, or reflected in, its density; molecular weight distributions; component weight fraction amount; viscoelastic properties; and environmental stress-cracking resistance. Additional inventive embodiments include a method of making the copolymer, a formulation comprising the copolymer and at least one additive that is different than the copolymer, a method of making a manufactured article from the copolymer or formulation; the manufactured article made thereby, and use of the manufactured article.

Abstract: A bimodal poly(ethylene-co-1-alkene) copolymer comprising a higher molecular weight poly(ethylene-co-1-alkene) copolymer component and a lower molecular weight poly(ethylene-co-1-alkene) copolymer component. The copolymer is characterized by a unique combination of features comprising, or reflected in, its density; molecular weight distributions; component weight fraction amount; and viscoelastic properties; and at least one of environmental stress-cracking resistance and resin swell. Additional inventive embodiments include a method of making the copolymer, a formulation comprising the copolymer and at least one additive that is different than the copolymer, a method of making a manufactured article from the copolymer or formulation; the manufactured article made thereby, and use of the manufactured article.

Abstract: The present invention provides polyethylene-based compositions suitable for packaging applications, films, and articles. In one aspect, a polyethylene-based composition suitable for packaging applications comprises (a) at least 97% by weight, based on the total weight of the polyethylene-based composition, of a polyethylene composition comprising: (i) from 25 to 37 percent by weight of a first polyethylene fraction having a density in the range of 0.935 to 0.947 g/cm3 and a melt index (I2) of less than 0.1 g/10 minutes; and (ii) from 63 to 75 percent by weight of a second polyethylene fraction; and (b) 90 to 540 ppm, based on the total weight of the polyethylene-based composition of a calcium salt of 1,2-cyclohexanedicarboxylic acid; wherein the polyethylene composition has less than 0.10 branches per 1,000 carbon atoms when measured using 13C NMR, wherein the density of the polyethylene-based composition N is at least 0.965 g/cm3, and wherein the melt index (I2) of the polyethylene-based composition is 0.

Abstract: In various embodiments, a polyethylene formulation has a density of greater than 0.940 g/cm3 when measured according to ASTM D792, and a high load melt index (I21) of 1.0 g/10 min to 10.0 g/10 min when measured according to ASTM D1238 at 190° C. and a 21.6 kg load. Moreover, the polyethylene formulation has a peak molecular weight (Mp(GPC)) of less than 50,000 g/mol, a number average molecular weight (Mn(GPC)) of less than 30,000 g/mol, and a weight fraction (w1) of molecular weight (MW) less than 10,000 g/mol of less than or equal to 10.5 wt %, as determined by Gel Permeation Chromatography (GPC). Articles made from the polyethylene formulation, such as articles made by blow molding processes are also provided.

Abstract: Formulations and methods are disclosed which provide controlled, sustained release of a biologic therapeutic to a space within the body. More specifically, formulations comprising a plurality of hydrophilic polymer strands, and methods of forming and administering such formulations, are disclosed. In some embodiments, the formulations exhibit a burst release, an initial release, a triphasic release, and release over thirty to ninety days of the biologic therapeutic. In some embodiments, the formulations exhibit reversible precipitation of the biologic therapeutic into precipitates having a diameter of about 50 nm to about 10 ?m.

Abstract: Formulations and methods are disclosed which provide controlled, sustained release of a biologic therapeutic to a space within the body. More specifically, formulations comprising a plurality of hydrophilic polymer strands, and methods of forming and administering such formulations, are disclosed. In some embodiments, the formulations exhibit a burst release, an initial release, a triphasic release, and release over thirty to ninety days of the biologic therapeutic. In some embodiments, the formulations exhibit reversible precipitation of the biologic therapeutic into precipitates having a diameter of about 50 nm to about 10 ?m.

Abstract: Formulations and methods are disclosed which provide controlled, sustained release of a biologic therapeutic to a space within the body. More specifically, formulations comprising a plurality of hydrophilic polymer strands, and methods of forming and administering such formulations, are disclosed. In some embodiments, the formulations exhibit a burst release, an initial release, a triphasic release, and release over thirty to ninety days of the biologic therapeutic. In some embodiments, the formulations exhibit reversible precipitation of the biologic therapeutic into precipitates having a diameter of about 50 nm to about 10 ?m.